Carabersat

Carabersat

SCHEMBL3300409

CC(=O)c1ccc2c(c1)C(NC(=O)c1ccc(F)cc1)C(O)C(C)(C)O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 5/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carabersat SCHEMBL261192 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL29373163 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL9287969 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL27418709 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3308650 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3301553 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3301548 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL27394684 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL5317948 0.99 ABCC9 (0.64) ABCC9
Carabersat SCHEMBL5317945 0.99 ABCC9 (0.64) ABCC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC. (GB) 2010-04-22 US claimed
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC 2007-04-19 US claimed
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2003-12-25 US claimed
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2002-09-05 US claimed
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2001-09-13 US claimed
EP-0673374-B1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-03-01 EP claimed
US-5948811-A Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEEGHAM P.L.C. (GB) 1999-09-07 US claimed
EP-0673374-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1995-09-27 EP claimed
WO-1994013657-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1994-06-23 WO claimed
CN-1088203-A New therapy SMITHKLINE BEECHAM PLC (GB) 1994-06-22 CN claimed
WO-1994012173-A1 BENZOPYRON ANALOGUES FOR THE TREATMENT OF ANXIETY, MANIA, DEPRESSION OR WITHDRAWAL SYMPTOMS SMITHKLINE BEECHAM PLC (GB) 1994-06-09 WO claimed
EP-0126311-B1 BENZOPYRAN DERIVATIVES. BEECHAM GROUP PLC (GB) 1989-09-13 EP claimed
US-4571406-A Anti-hypertensive chromans and chromenes BEECHAM GROUP P.L.C. (GB) 1986-02-18 US claimed
EP-0126311-A2 Benzopyran derivatives. BEECHAM GROUP PLC (GB) 1984-11-28 EP claimed
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC. (GB) 2010-04-22 US disclosed
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC 2007-04-19 US disclosed
EP-0939630-B1 USE OF BENZOPYRANOLS TO TREAT NEUROLOGICAL DISORDERS SMITHKLINE BEECHAM PLC (GB) 2004-06-30 EP disclosed
EP-0587645-A1 BENZO- AND PYRIDOPYRAN DERIVATIVES HAVING ANXIOLYTIC AND ANTI-CONVULSANT ACTIVITY SMITHKLINE BEECHAM PLC (GB) 1994-03-23 EP disclosed
WO-1992022293-A1 BENZO- AND PYRIDOPYRAN DERIVATIVES HAVING ANXIOLYTIC AND ANTI-CONVULSANT ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 1992-12-23 WO disclosed
EP-0126311-B1 BENZOPYRAN DERIVATIVES. BEECHAM GROUP PLC (GB) 1989-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6 ABCC9 162/4885
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH, CBR3 ABCC9 155/4885
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CLIC1, NAF1 ABCC9 122/4885
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SNCA, GRIN2C, PYGB ABCC9 1314/4885
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH ABCC9 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.